BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Lung Summit//ESMO26_LungCancerTop10//EN
CALSCALE:GREGORIAN
X-WR-CALNAME:ESMO26_LungCancerTop10
X-WR-CALDESC:Top 10 abstracts at ESMO Congress 2026\, selected by Dr. Mehrp
 ouya Mobin. All times Madrid local time (CEST to 24 October\, CET from 25 
 October).
X-WR-TIMEZONE:Europe/Madrid
BEGIN:VTIMEZONE
TZID:Europe/Madrid
BEGIN:DAYLIGHT
DTSTART:19810329T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:19961027T030000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:esmo26-lba3@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261024T171800
DTEND;TZID=Europe/Madrid:20261024T173000
SUMMARY:LBA3 Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance 
 (1LM) therapy following durva\, platinum\, and etoposide (1L durva + EP) i
 n extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of th
 e phase 3 DeLLphi-305 trial
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (
 1LM) therapy following durva\, platinum\, and etoposide (1L durva + EP) in
  extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the
  phase 3 DeLLphi-305 trial\n\nPresenter: Jacob Sands\nAbstract: LBA3\nSess
 ion: Presidential Symposium I\nRoom: Alicante Auditorium - Hall 6\, IFEMA 
 Madrid\nCongress programme: https://cslide.ctimeetingtech.com/esmo2026/att
 endee/confcal/show/session/346\n\nOne of the Top 10 abstracts at ESMO Cong
 ress 2026\, selected by Dr. Mehrpouya Mobin. More at https://lungsummit.or
 g
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/346
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba66@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261025T105300
DTEND;TZID=Europe/Madrid:20261025T110300
SUMMARY:LBA66 Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) vers
 us chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatmen
 t for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3
  OptiTROP-Lung06 study
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus
  chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment 
 for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 O
 ptiTROP-Lung06 study\n\nPresenter: Caicun Zhou\nAbstract: LBA66\nSession: 
 Proffered paper 1: NSCLC\, metastatic\nRoom: Alicante Auditorium - Hall 6
 \, IFEMA Madrid\nCongress programme: https://cslide.ctimeetingtech.com/esm
 o2026/attendee/confcal/show/session/272\n\nOne of the Top 10 abstracts at 
 ESMO Congress 2026\, selected by Dr. Mehrpouya Mobin. More at https://lung
 summit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/272
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba67@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261025T110300
DTEND;TZID=Europe/Madrid:20261025T111300
SUMMARY:LBA67 Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus
  platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (N
 SCLC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus p
 latinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSC
 LC) after progression on EGFR-TKI: phase III OptiTROP-Lung04 study\n\nPres
 enter: Wen Feng Fang\nAbstract: LBA67\nSession: Proffered paper 1: NSCLC\,
  metastatic\nRoom: Alicante Auditorium - Hall 6\, IFEMA Madrid\nCongress p
 rogramme: https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show
 /session/272\n\nOne of the Top 10 abstracts at ESMO Congress 2026\, select
 ed by Dr. Mehrpouya Mobin. More at https://lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/272
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba68@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261025T111300
DTEND;TZID=Europe/Madrid:20261025T112300
SUMMARY:LBA68 Phase 3 study of sigvotatug vedotin (SV) vs docetaxel (DTX) i
 n previously treated nonsquamous non-small cell lung cancer (NSCLC)
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Phase 3 study of sigvotatug vedotin (SV) vs docetaxel (DTX) in 
 previously treated nonsquamous non-small cell lung cancer (NSCLC)\n\nPrese
 nter: Solange Peters\nAbstract: LBA68\nSession: Proffered paper 1: NSCLC\,
  metastatic\nRoom: Alicante Auditorium - Hall 6\, IFEMA Madrid\nCongress p
 rogramme: https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show
 /session/272\n\nOne of the Top 10 abstracts at ESMO Congress 2026\, select
 ed by Dr. Mehrpouya Mobin. More at https://lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/272
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba5@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261025T163000
DTEND;TZID=Europe/Madrid:20261025T164200
SUMMARY:LBA5 Krascendo 1: efficacy and safety of divarasib (diva) vs sotora
 sib (soto) or adagrasib (ada) in previously treated locally advanced or me
 tastatic KRAS G12C-mutated NSCLC
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Krascendo 1: efficacy and safety of divarasib (diva) vs sotoras
 ib (soto) or adagrasib (ada) in previously treated locally advanced or met
 astatic KRAS G12C-mutated NSCLC\n\nPresenter: Ferdinandos Skoulidis\nAbstr
 act: LBA5\nSession: Presidential Symposium II\nRoom: Alicante Auditorium -
  Hall 6\, IFEMA Madrid\nCongress programme: https://cslide.ctimeetingtech.
 com/esmo2026/attendee/confcal/show/session/348\n\nOne of the Top 10 abstra
 cts at ESMO Congress 2026\, selected by Dr. Mehrpouya Mobin. More at https
 ://lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/348
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba6@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261025T165400
DTEND;TZID=Europe/Madrid:20261025T170600
SUMMARY:LBA6 Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexe
 d (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) adv
 anced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed
  (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) adva
 nced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results\n\nPresenter: Sh
 un Lu\nAbstract: LBA6\nSession: Presidential Symposium II\nRoom: Alicante 
 Auditorium - Hall 6\, IFEMA Madrid\nCongress programme: https://cslide.cti
 meetingtech.com/esmo2026/attendee/confcal/show/session/348\n\nOne of the T
 op 10 abstracts at ESMO Congress 2026\, selected by Dr. Mehrpouya Mobin. M
 ore at https://lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/348
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba69@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261026T083000
DTEND;TZID=Europe/Madrid:20261026T084000
SUMMARY:LBA69 Savolitinib or Placebo Combined with Osimertinib in Treatment
 -Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results 
 from the Phase 3 SANOVO Study
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Savolitinib or Placebo Combined with Osimertinib in Treatment-N
 aïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results fr
 om the Phase 3 SANOVO Study\n\nPresenter: Yi-Long Wu\nAbstract: LBA69\nSes
 sion: Proffered paper 2: NSCLC\, metastatic\nRoom: Alicante Auditorium - H
 all 6\, IFEMA Madrid\nCongress programme: https://cslide.ctimeetingtech.co
 m/esmo2026/attendee/confcal/show/session/283\n\nOne of the Top 10 abstract
 s at ESMO Congress 2026\, selected by Dr. Mehrpouya Mobin. More at https:/
 /lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/283
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba71@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261026T092200
DTEND;TZID=Europe/Madrid:20261026T093200
SUMMARY:LBA71 PANKU-Lung01: Randomized Phase III Study of Izalontamab Breng
 itecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer
  (NSCLC) After Progression on a Third Generation EGFR TKI
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:PANKU-Lung01: Randomized Phase III Study of Izalontamab Brengit
 ecan (iza-bren) in EGFR-Mutant Non-squamous Non‑Small Cell Lung Cancer (
 NSCLC) After Progression on a Third Generation EGFR TKI\n\nPresenter: Li Z
 hang\nAbstract: LBA71\nSession: Proffered paper 2: NSCLC\, metastatic\nRoo
 m: Alicante Auditorium - Hall 6\, IFEMA Madrid\nCongress programme: https:
 //cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/283\n\n
 One of the Top 10 abstracts at ESMO Congress 2026\, selected by Dr. Mehrpo
 uya Mobin. More at https://lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/283
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba72@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261026T093200
DTEND;TZID=Europe/Madrid:20261026T094200
SUMMARY:LBA72 Ruzaltatug rezetecan\, a HER3-directed ADC\, vs platinum-base
 d chemotherapy (PBC) in EGFR-mutated advanced NSCLC progressing after EGFR
 -TKI: interim analyses (IA) from the phase 3 HERON-Lung01 trial
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Ruzaltatug rezetecan\, a HER3-directed ADC\, vs platinum-based 
 chemotherapy (PBC) in EGFR-mutated advanced NSCLC progressing after EGFR-T
 KI: interim analyses (IA) from the phase 3 HERON-Lung01 trial\n\nPresenter
 : Yi-Long Wu\nAbstract: LBA72\nSession: Proffered paper 2: NSCLC\, metasta
 tic\nRoom: Alicante Auditorium - Hall 6\, IFEMA Madrid\nCongress programme
 : https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session
 /283\n\nOne of the Top 10 abstracts at ESMO Congress 2026\, selected by Dr
 . Mehrpouya Mobin. More at https://lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/283
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
UID:esmo26-lba64@lungsummit.org
SEQUENCE:1
DTSTAMP:20260929T093755Z
DTSTART;TZID=Europe/Madrid:20261026T152300
DTEND;TZID=Europe/Madrid:20261026T153300
SUMMARY:LBA64 Toripalimab plus chemotherapy as perioperative treatment for 
 resectable stage II or III non-small cell lung cancer (NSCLC): Final analy
 sis of the Phase 3 Neotorch study
LOCATION:Alicante Auditorium - Hall 6\, IFEMA Madrid
DESCRIPTION:Toripalimab plus chemotherapy as perioperative treatment for re
 sectable stage II or III non-small cell lung cancer (NSCLC): Final analysi
 s of the Phase 3 Neotorch study\n\nPresenter: Shun Lu\nAbstract: LBA64\nSe
 ssion: Proffered paper: Non-metastatic NSCLC and other thoracic malignanci
 es\nRoom: Alicante Auditorium - Hall 6\, IFEMA Madrid\nCongress programme:
  https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/
 292\n\nOne of the Top 10 abstracts at ESMO Congress 2026\, selected by Dr.
  Mehrpouya Mobin. More at https://lungsummit.org
URL:https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/sessio
 n/292
STATUS:CONFIRMED
TRANSP:OPAQUE
END:VEVENT
END:VCALENDAR